Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial

BACKGROUND: This analysis of the IMPACT study assessed the cardiovascular (CV) safety of single-inhaler triple therapy with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus FF/VI and UMEC/VI dual therapy. METHODS: IMPACT was a 52-week, randomized, double-blind, multicenter Phase III s...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Respir Res
Главные авторы: Day, Nicola C., Kumar, Subramanya, Criner, Gerard, Dransfield, Mark, Halpin, David M. G., Han, MeiLan K., Jones, C. Elaine, Kaisermann, Morrys C., Kilbride, Sally, Lange, Peter, Lomas, David A., Martin, Neil, Martinez, Fernando J., Singh, Dave, Wise, Robert, Lipson, David A.
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2020
Предметы:
Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7275457/
https://ncbi.nlm.nih.gov/pubmed/32503599
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-020-01398-w
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы